Scientists use High-Tech scans to track new liver drug
NCT ID NCT07069725
Summary
This early-stage study aims to see if an experimental oral drug, AZD2389, reaches and engages its intended target in the livers of people with advanced liver scarring (fibrosis). Researchers will use special PET scans to measure this in about 12 participants. The main goal is to gather information on how the drug behaves in the body, not to treat the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
WITHDRAWNSolna, 171 64, Sweden
-
Research Site
RECRUITINGStockholm, 17176, Sweden
Conditions
Explore the condition pages connected to this study.